|
Originally published In Press as doi:10.1074/jbc.M106645200 on September 5, 2001
J. Biol. Chem., Vol. 276, Issue 46, 43428-43434, November 16, 2001
Thyroid Hormone Receptor-interacting Protein 1 Modulates Cytokine and Nuclear Hormone Signaling in Erythroid
Cells*
Evan
Ingley ,
David
Chappell §,
Sally Y. K.
Poon ,
Mohinda K.
Sarna ,
Jennifer G.
Beaumont ¶,
James H.
Williams ,
Justin P.
Stillitano ,
Schickwann
Tsai ,
Peter J.
Leedman ,
Peta A.
Tilbrook , and
S. Peter
Klinken **
From the Laboratory for Cancer Medicine, Western
Australian Institute for Medical Research, Royal Perth Hospital and the
Department of Biochemistry, University of Western Australia, Perth,
Western Australia 6000, Australia and The Institute for Gene
Therapy and Molecular Medicine, Mount Sinai School of Medicine, New
York, New York 10030
Received for publication, July 16, 2001, and in revised form, August 15, 2001
 |
ABSTRACT |
Erythropoietin (Epo) and thyroid hormone
(T3) are key molecules in the development of red
blood cells. We have shown previously that the tyrosine kinase Lyn is
involved in differentiation signals emanating from an activated
erythropoietin receptor. Here we demonstrate that Lyn interacts with
thyroid hormone receptor-interacting protein 1 (Trip-1), a
transcriptional regulator associated with the T3 receptor,
providing a link between the Epo and T3 signaling pathways. Trip-1 co-localized with Lyn and the T3 receptor in the
cytoplasm/plasma membrane of erythroid cells but translocated to
discrete nuclear foci shortly after Epo-induced differentiation. Our
data reveal that T3 stimulated the proliferation of
immature erythroid cells, and inhibited maturation promoted by
erythropoietin. Removal of T3 reduced cell division and
enhanced terminal differentiation. This was accompanied by large
increases in the cell cycle inhibitor p27Kip1 and by
increasing expression of erythroid transcription factors GATA-1, EKLF,
and NF-E2. Strikingly, a truncated Trip-1 inhibited both
erythropoietin-induced maturation and T3-initiated cell
division. This mutant Trip-1 acted in a dominant negative fashion by
eliminating endogenous Lyn, elevating p27Kip1, and blocking
T3 response elements. These data demonstrate that Trip-1
can simultaneously modulate responses involving both cytokine and
nuclear receptors.
 |
INTRODUCTION |
Erythropoiesis, the process of generating red blood cells, is
controlled by hormones that bind to cytokine receptor and nuclear hormone receptor families (1, 2). Two well characterized molecules that
strongly influence erythropoiesis are erythropoietin (Epo)1 and thyroid hormone
(T3). Epo binds to a cell surface receptor of the cytokine
receptor family (3), initiating an intracellular signaling cascade that
has been deciphered gradually over the past decade (reviewed in Refs.
4-7). Numerous signaling proteins are activated by Epo, including
JAK2, STAT5, Ras, phosphatidylinositol 3-kinase, phospholipase
C , and MAP kinase (5, 7); activation of negative regulators such as
SHP1, SOCS1, and CIS also occurs after receptor engagement
(8-10).
T3 binds to the intracellular thyroid hormone receptor
(TR), a member of the nuclear hormone receptor family, which regulates gene expression (11). T3 has a potent effect on
erythropoiesis, especially in hypothyroid patients who are often
anemic; however, erythroid hyperplasia can occur in individuals with
hyperthyroidism (12, 13). It is noteworthy that the TR isoform is
expressed preferentially in differentiating erythroid cells (14) and
that the v-erbA oncogene involved in avian erythroleukemia
represents a mutated form of TR (15, 16). Studies with whole animals have indicated that T3 stimulates erythropoiesis (17),
whereas in vitro assays have shown that T3
inhibits colony formation by erythroid progenitors (18, 19). The
elegant studies of Beug and colleagues (19-24) have
demonstrated that the balance between proliferation and differentiation
can be altered by the introduction of exogenous TR
(c-erbA) or v-erbA into immature avian red blood cells.
We have examined Epo-initiated signaling in J2E erythroid cells as they
proliferate, remain viable, produce hemoglobin, and undergo
morphological maturation in response to Epo (25-27). Following Epo
stimulation of these cells, phosphorylation changes to the Epo
receptor, JAK2, STAT5, Ras-GAP, phosphatidylinositol 3-kinase, phospholipase C , and MAP kinase are identical to the kinetics reported in other cell systems (28). The tyrosine kinase Lyn is crucial
for Epo-induced differentiation of immature J2E and R11 cell lines
(27). Lyn associates with the Epo receptor and can phosphorylate the
receptor and STAT5 in vitro (28, 29). As the most abundant
Src family kinase in red blood cells (30), Lyn also phosphorylates key
erythrocyte membrane proteins (31). Our recent data indicate JAK2 is
the primary kinase that initiates Epo signaling and that Lyn acts as a
secondary kinase to promote differentiation (32). Significantly, the
erythroid progenitor compartment is altered in Lyn /
mice.2
In this study we attempted to identify downstream effectors of Lyn in
erythroid cells using a yeast two-hybrid screen. HS1, a known target
for Src family kinases including Lyn, was identified in this screen and
its effects on erythroid differentiation demonstrated (33). Here, we
report on the interaction between Lyn and thyroid hormone
receptor-interacting protein 1 (Trip-1), a transcriptional regulator
that associates with TR (34-36). The Lyn/Trip-1 association, therefore, provides a link between the Epo and T3 signaling pathways.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture--
Cells were grown in Dulbecco's modified
Eagle's medium, 5% fetal calf serum, or serum depleted of
T3 (24). T3 could not be detected in depleted
sera by radioimmunoassay. The Epo-responsive J2E (25) and R11 (37) cell
lines were derived from murine fetal liver cells transduced with
retroviruses expressing v-Raf/v-Myc (J2E) or v-Raf (R11).
Differentiation of J2E and R11 cell lines was initiated with Epo (5 units/ml). Nuclear hormones were used at a final concentration of 1 µM. Viability was determined by eosin dye exclusion and
hemoglobin synthesis by benzidine staining (28). Cell morphology was
examined following cytocentrifugation onto glass slides and
Wright-Giemsa staining (26). Proliferation was assayed by
[3H]thymidine incorporation (26). Fetal liver cells were
plated in methylcellulose for CFU-E and BFU-E assays as described
previously (38) before benzidine-positive colonies were enumerated. All graphical data are represented as the mean ± S.D.
(n 3).
Yeast Two-hybrid Analysis--
The yeast two-hybrid system (33,
39) utilized the S. cerevisiae L40 strain. Wild-type Lyn
(Lyn) and a dominant negative Lyn (Y397F) cDNAs were used to screen
a yeast two-hybrid library derived from the lymphohemopoietic
progenitor cell line EML C.1 (40) as described previously (33). The
plasmids expressing VP16 fusions of full-length Trip-1 (pVP16-Trip-1),
amino acids 1-150 (pVP16-Trip-1-CC-A), and the coiled-coil domain,
amino acids 50-100 (pVP16-Trip-1-CC) were generated by ligating
polymerase chain reaction fragments into pVP16.
In Vitro Binding Assay--
Plasmids expressing Glutathione
S-transferase (GST) fusion proteins of Lyn (pGEX-Lyn) and
Trip-1 (amino acids 1-171) (pGEX-Trip-1-171) were generated by
ligating polymerase chain reaction fragments into pGEX-2T. GST fusion
proteins were purified as described previously (33). Binding
experiments were performed by the addition of purified soluble Trip-1
(100 ng) to GST, GST-Lyn, GST-LynY397F, or GST-LynUn (500 ng) attached
to glutathione-agarose beads in buffer (33) and then incubated at
4 °C for 2 h. Bound Trip-1 was detected by SDS-polyacrylamide
electrophoresis and immunoblotting using an anti-Trip-1 antibody
(36).
Immunoprecipitation and Immunoblotting--
Cells were lysed as
described previously (33), and proteins were co-immunoprecipitated with
antibodies (anti-Trip-1 (41), anti-EpoR (no. 187), anti-Lyn;
SC-15G, anti-STAT5; SC-1081, anti-TR ; SC-772, Santa Cruz
Biotechnology Inc., Santa Cruz, CA) for 2 h at 4 °C and then
collected with protein A-Sepharose beads for 16 h before analysis
by immunoblotting. Additional antibodies used in immunoblotting were
directed against Lyn, Lck, Src, Hck, Fyn, Syk, MAPK, v-Raf,
phosphotyrosine and GATA-1 (SC-15, SC-13, SC-19, SC-72, SC-16, SC-573,
SC-154, SC-133, SC-7020, and SC-265, Santa Cruz). Antibodies to EKLF,
NF-E2, globin (catalog no. 55447, Cappel Research, Organon Technika,
Boxtel, The Netherlands), and p27Kip1 and
p57Kip2 (catalog no. 13231A and 65021A, respectively,
PharMingen, San Diego, CA) were also used for immunoblotting. Secondary
antibodies were coupled to horseradish peroxidase and detected by
enhanced chemiluminescence (Amersham Pharmacia Biotech, Little
Chalfont, Buckinghamshire, UK).
Indirect Immunofluorescent Microscopy--
Cells were
cytocentrifuged onto slides, fixed in 50% methanol, 50% acetone, and
then stained for indirect immunofluorescence using anti-Lyn,
anti-Trip-1 (41), or anti-TR antibodies and AlexaFluor-conjugated
anti-rabbit and anti-mouse secondary antibodies (Molecular Probes,
Eugene, OR). DNA was counterstained with Hoechst 33258. Slides were
mounted in 50 mM Tris-HCl, pH 8.0, 50% glycerol, 2.5%
1,4-diazabicyclo-[2.2.2]octane and visualized using a Bio-Rad MRC-1000/1024 UV laser scanning confocal microscope (Bio-Rad, Hercules, CA).
Retroviral Infection of Cells--
Sense (Cs) and antisense
(C ) tTrip-1 cDNAs encoding amino acids 1-171 were generated by
polymerase chain reaction, and the fragments were subcloned into the
pMSCV2.2neo vector (42). Amphotropic and ecotropic retroviruses
expressing the Cs and C constructs were used to infect erythroid
cells as described previously (33). The efficiency of fetal liver cell
infection was at least 50% (43). Numerous independent clones were
isolated, and representative clones are shown.
Transient Transfection Assays--
Cells (107) were
electroporated with 10 µg of the TR reporter constructs pF2-Luc or
pDR4-Luc (44) and 1 µg of pRL-SV40 (Promega, Madison, WI) at 300 V/1000 microfarad using a Gene Pulser II (Bio-Rad). Transfected
cells were harvested after 48 h of culture in the presence or
absence of T3, and dual luciferase reporter assays were
performed (Promega) on an Autolumat LB953 (EG&G Berthold, Oak Ridge, TN).
 |
RESULTS |
Trip-1 Associates with Lyn and TR --
To identify specific
binding partners of Lyn, a yeast two-hybrid screen was conducted using
wild-type Lyn and the kinase-inactive Y397F mutant (33); Fig.
1A shows the association of
Lyn with Trip-1. In addition to transcriptionally regulating TR
(34-36), Trip-1 also possesses intrinsic helicase activity, and
independently it has also been described as SUG1, a component of the
26-S proteasome (41, 45).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 1.
Lyn associates with Trip-1.
A, Lyn and Trip-1 interact in the yeast two-hybrid system.
His3 assays of yeast co-expressing LexA fusions of Lyn,
LynY397F (kinase inactive Lyn), or HLS7 (negative control) (43) with a
VP16 fusion of Trip-1. B, purified Lyn and Trip-1 interact
in vitro. Immunoblot analysis of a binding assay with
purified Trip-1 (amino acids 1-171) and GST fusions of Lyn, LynY397F,
or the Unique plus SH3 domain (LynUN-SH3). C, the
SH2 and SH3 domains of Lyn bind Trip-1. Yeast co-expressing LexA
fusions of Lyn, LynY397F, Lyn 243, LynUn (Unique), LynSH3, or LynSH2
and a VP16 fusion of Trip-1 were assayed for -galactosidase
( -gal) activity. D, the coiled-coil
(CC) containing amino-terminal domain of Trip-1 binds Lyn.
Yeast co-expressing pVP16 fusions of Trip-1, Trip-1-CC-A, or Trip-1-CC
and Lyn were assayed for -galactosidase activity. E, Lyn,
Trip-1, and TR interact in vivo. J2E and R11 cells were
lysed, and then Trip-1 (or TR ) was immunoprecipitated, and
co-immunoprecipitation of Lyn, Trip-1, or TR was detected by
immunoblotting.
|
|
In vitro studies with purified proteins revealed that Lyn
and Trip-1 interacted directly (Fig. 1B) in a
phosphotyrosine-independent manner (Fig. 1, A-C). Trip-1
also bound the kinase-inactive Y397F mutant of Lyn (Fig. 1,
A and B), indicating that the enzymatic activity
of Lyn was not required for this association. Deletion analyses showed
that the SH2 and, to a lesser extent, the SH3 domains of Lyn were
responsible for Trip-1 binding in vitro (Fig. 1,
B and C); these observations were confirmed using
lysates from erythroid cells (data not shown). The regions of Trip-1
that bound Lyn were then analyzed. Fig. 1D shows that the
amino-terminal of Trip-1 but not the coiled-coil domain alone was
required for Lyn binding. This region is distinct from the highly
conserved ATPase/DNA helicase AAA (ATPase
associate with a variety of cellular activities) domain of Trip-1 needed to bind the TR
(41).
Co-immunoprecipitation experiments performed on lysates from erythroid
cell lines show that Lyn does indeed associate with Trip-1 in
vivo (Fig. 1E). Similarly, Trip-1 and TR
co-immunoprecipitated in these cells. These studies show that Trip-1 is
able to bind both Lyn and TR in erythroid cells, thereby connecting
discrete signaling pathways involving Epo and T3.
Trip-1 Co-localizes with Lyn and TR in the Cytoplasm of
Erythroid Cells--
Having established a biochemical interaction
between Lyn and Trip-1, the subcellular localization of these proteins
was ascertained in uninduced erythroid cells. Lyn was found primarily
in the cytoplasm of erythroid cells, with significant concentration at
the plasma membrane (Fig. 2A).
As Trip-1 was also distributed in the cytosol and plasma membrane,
appreciable co-localization between Lyn and Trip-1 was observed (Fig.
2A). As described by Zhu et al. (46), TR was
detected in both the cytoplasm and nucleus. Consequently, Trip-1
co-localized with TR in the cytoplasm, but not the nucleus, of these
unstimulated erythroid cells (Fig. 2B). Comparable results were obtained with other erythroid cells (data not shown). These experiments demonstrate that the association of Trip-1 with Lyn and
TR occurs in the cytoplasm/plasma membrane of erythroid cells.

View larger version (82K):
[in this window]
[in a new window]
|
Fig. 2.
Cytoplasmic co-localization of Trip-1
with Lyn and TR . A, Lyn and
Trip-1 can localize in the cytoplasm and plasma membrane. Erythroid
cells were fixed on slides and analyzed by confocal microscopy
utilizing antibodies to Lyn and Trip-1. Areas of Lyn (green)
and Trip-1 (red) co-localization are yellow (Lyn + Trip-1). B, TR and Trip-1 co-localize in the cytoplasm
of erythroid cells. Cells were analyzed as above with antibodies to
TR and Trip-1. Areas of TR (green) and Trip-1
(red) co-localization are yellow (TR + Trip-1).
|
|
T3 Inhibits Epo-induced Differentiation--
As both
Epo and T3 affect erythropoiesis (1, 2), and Trip-1 was
shown to associate with Lyn and TR (Figs. 1 and 2), biological
evidence for interplay between these pathways was sought. To this end,
T3 and Epo concentrations were manipulated and cellular responses monitored. Fig. 3A
shows that the removal of T3 enhanced Epo-induced
hemoglobin production, whereas the addition of T3 severely
impeded synthesis of the oxygen carrier. These effects were
T3-specific, as reverse T3 (Fig. 3A)
and a variety of nuclear hormones (data not shown) had no effect on
differentiation. The inhibitory effects of T3 on hemoglobin
synthesis were concentration-dependent with an
IC50 of 100 pM. Furthermore, morphological
maturation was severely retarded in the presence of T3;
nuclear condensation, cytoplasmic acidophilia, reduced cell size, and
enucleation were all restricted by T3 (Fig. 3B).
Conversely, removal of T3 accelerated the appearance of
erythroid cells with a more mature phenotype, in particular
orthochromatic erythroblasts and reticulocytes. Identical results were
obtained with other Epo-responsive cell lines (data not shown).

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 3.
T3 inhibits hemoglobin production
and promotes erythroid proliferation. A, J2E cells were
cultured as indicated for 48 h then assayed for hemoglobin content
by benzidine staining. FCS, fetal calf serum;
dFCS, fetal calf serum-depleted of T3;
rT3, reverse T3. B, J2E cells
were cultured as indicated for 48 h before morphological changes
were analyzed. R, reticulocytes. C, J2E cells
were cultured as indicated and then assayed for DNA synthesis by
[3H]thymidine uptake.
|
|
In marked contrast with the inhibition of Epo-initiated
differentiation, T3 promoted [ 3H]thymidine
uptake (Fig. 3C). When T3 was removed from
cultures, DNA synthesis almost ceased; however, replication resumed
upon re-introduction of T3. This observation was supported
by monitoring cell numbers in these cultures (data not shown).
To extend the analysis of erythroid cells beyond cell lines, the
Epo/T3 axis was examined in red cell progenitors from
murine fetal livers. Fig. 4A
shows that the inhibitory effects of T3 on differentiation
were not restricted to immortalized cells, as increasing the
T3 concentration reduced Epo-induced colonies from normal
progenitors. However, the effect was more pronounced on erythroid
colony-forming units (CFU-E) than erythroid burst-forming units
(BFU-E). These data indicate that T3 also had an inhibitory effect on Epo-induced differentiation of normal erythroid cells.

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 4.
T3 affects erythroid colony
formation. A, fetal liver cells were plated in
methylcellulose (colony numbers/5,000 fetal liver cells plated are
shown) in the presence of Epo with (filled bars) or without
(open bars) T3. An asterisk indicates
a significant decrease in colony number in the presence of
T3 (p < 0.01, n = 3).
B, fetal liver cells were incubated in the presence or
absence of T3 for 3 days before being plated in
methylcellulose with Epo (filled bars) or without Epo
(open bars). An asterisk indicates a significant
increase in colony number with T3 pre-incubation
(p < 0.01, n = 3).
|
|
To determine whether T3 affected fetal liver erythroid
progenitors before exposure to Epo, cells were pre-incubated
with T3 and then treated with Epo. Intriguingly, when
T3 was added prior to Epo, both the BFU-E and CFU-E numbers
rose (Fig. 4B). This expansion of the erythroid progenitor
compartment by pre-incubation with T3 indicates that the
effects of T3 are stage-specific. Taken together these
results show that T3 promotes proliferation and the
expansion of immature erythroid cells at the expense of maturation, whereas Epo favors terminal differentiation toward a nonreplicating state.
T3 Affects Erythroid Transcription Factors and
p27Kip1--
To identify the biochemical mechanism for the
effects of T3 on erythroid proliferation and
differentiation, an immunoblot analysis was performed on key
transcription factors and cell cycle regulators. The effects of
T3 were quite striking as the levels of
erythroid-restricted transcription factors EKLF, NF-E2, and GATA-1 rose
3-10-fold when T3 concentrations were reduced (Fig. 5, left). In addition,
withdrawal of T3 resulted in a 20-fold increase in
p27Kip1, a cell cycle inhibitor important for the
maturation of erythroid cells (47, 48). In contrast, no change was
observed in p57Kip2 (Fig. 5, right).
Interestingly, the Lyn and TR content doubled when cells were
cultured in T3-depleted media. These observations provide
biochemical explanations for enhanced differentiation and restricted
replication after T3 withdrawal i.e. raised
GATA-1, EKLF, and NF-E2 facilitate red cell maturation, whereas
elevated p27Kip1 enables cells to exit the cell cycle and
enter the terminally differentiated state. At this stage it is unclear
whether the addition of T3 increases the frequency of
immature cells containing less EKLF, NF-E2, and GATA-1 or directly
reduces the expression of these factors in erythroid cells.

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 5.
T3 suppresses erythroid
transcription factors and p27. J2E and R11 cells were
cultured with or without T3 for 48 h, and then
proteins were extracted and analyzed by immunoblotting.
Constitutively expressed v-Raf was used as a loading
control.
|
|
Trip-1 Affects Responsiveness to Epo and T3--
To
determine whether Trip-1 could simultaneously regulate differentiation
signaling by Epo and proliferation promoted by T3, a
truncated Trip-1 (tTrip-1) encompassing the Lyn-binding domain (Fig.
1D) was introduced into J2E cells. Numerous independently isolated transfectants were termed JCs cells, whereas the
antisense controls were labeled JC . Significantly, tTrip-1 had a
marked inhibitory effect on Epo-induced hemoglobin production and
morphological maturation; very few hemoglobin-synthesizing cells were
detected in JCs cultures, and the cells were incapable of proceeding
beyond the proerythroblast/basophilic erythroblast boundary of
maturation (Fig. 6, A and
B). Moreover, T3-induced proliferation was
severely impeded (Fig. 6C). In contrast, the antisense
controls behaved like control cells or those infected with the
retroviral vector alone (data not shown). These data demonstrate that
the truncated Trip-1 acted in a dominant negative manner and had a
profound impact on both Epo-induced differentiation
and T3-promoted cell division.

View larger version (24K):
[in this window]
[in a new window]
|
Fig. 6.
tTrip-1 inhibits Epo and T3
responses. A, JC 1 (antisense control cells) and JCs4
(tTrip-1 expressing cells) were cultured in the presence (filled
bars) or absence (open bars) of Epo for 48 h and
then assayed for hemoglobin content. The asterisk indicates
a significant decrease in Epo-induced hemoglobin production
(p < 0.01, n = 3). B,
JC 1 and JCs4 cells were cultured in the presence or absence of
T3 for 48 h, and then morphological maturation was
examined. Reticulocytes (R) and enucleating erythroblasts
(E) are indicated. C, JC 1 and JCs4 cells were
cultured in the presence (filled bars) or absence
(open bars) of T3 for 48 h before cell
numbers were determined. The asterisk indicates a
significant decrease in T3-induced proliferation
(p < 0.01, n = 3).
|
|
The effect of tTrip-1 on normal erythroid progenitors was investigated
by infecting fetal liver cells and observing colony formation.
Consistent with the effects of tTrip-1 on cell lines, the truncated
Trip-1 decreased the number of Epo-induced BFU-E and CFU-E (Fig.
7A). Furthermore, tTrip-1
greatly diminished the ability of T3 pre-incubation to
expand the progenitor compartment (Fig. 7B). It was
concluded from these experiments that Trip-1 plays an important role in
regulating the responses of normal as well as immortalized
erythroid cells to Epo and T3.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
tTrip-1 affects erythroid colony
formation. A, erythroid progenitors in fetal liver were
infected with retroviruses expressing tTrip-1 (S) or an
antisense control (AS), and then colonies were determined in
the presence (filled bars) or absence (open bars)
of Epo. Cells were plated as described in Fig. 4A. An
asterisk indicates a significant decrease in Epo-induced
colony number (p < 0.05, n = 3).
B, fetal liver cells were infected with retroviruses as
described in A in the presence or absence of T3
for 3 days of pre-incubation before BFU-E formation in the presence
(filled bars) or absence (open bars) of Epo was
ascertained. The asterisk indicates a significant decrease
in T3-induced enhanced colony formation (p < 0.01, n = 3).
|
|
tTrip-1 Affects Lyn and p27Kip1 Levels--
The
biochemical mechanisms by which tTrip-1 inhibited Epo and
T3 action were then investigated. The inhibition of
Epo-induced differentiation by tTrip-1 coincided with the elimination
of Lyn but not other tyrosine kinases such as Fyn, Src, Syk, Lck, and Hck (Fig. 8A and data not
shown). Conversely, the elevated levels of p27Kip1 in JCs
cells correlated with reduced proliferation (Fig. 8A). However, the inability to differentiate was not caused by a reduction in GATA-1, EKLF, NF-E2, globins, or endogenous Trip-1 (Fig.
8A), nor was it due to restricted phosphorylation of the Epo
receptor or STAT5 (data not shown). It is noteworthy that the antisense control did not affect Trip-1 protein levels, validating its use as an
additional control (Figs. 6 and 7).

View larger version (42K):
[in this window]
[in a new window]
|
Fig. 8.
tTrip-1 induces biochemical changes.
A, JC 1 and JCs4 cell lysates were analyzed by
immunoblotting for tTrip-1, Trip-1, Lyn, Fyn, p57Kip2,
p27Kip1, TR , and v-Raf (loading control).
B, JC 1 and JCs4 cells were transiently transfected with
the F2 (inverted palindrome T3 response element) reporter
plasmids (44). After 48 h in the presence (filled bars)
or absence (open bars) of T3, cells were
analyzed for luciferase activity (RLU, relative light units;
measured relative to control luciferase activity). The
asterisk indicates a significant suppression in
T3-induced reporter activity (p < 0.01, n = 3).
|
|
To determine whether tTrip-1 also interfered with
T3-induced transcription, activation of T3
response elements was examined in JCs cells. The cells were transfected
with either direct repeats or inverted palindromes of the
T3 response elements and were then exposed to
T3. Significantly tTrip-1 negated the T3
responsiveness of both elements (Fig. 8B and data not
shown). It was concluded from this series of experiments that tTrip-1
blocked erythroid differentiation and proliferation by suppressing
endogenous Lyn, increasing p27Kip1 and interfering with the
transcriptional activity of T3 response elements.
Trip-1 Translocates to the Nucleus during Erythroid
Differentiation--
Trip-1 localized primarily in the cytoplasm of
uninduced erythroid cells (Fig. 2). The subcellular localization of
this protein was then examined in cells stimulated with Epo or when
T3 was withdrawn from culture. Strikingly, cytoplasmic
Trip-1 translocated to discrete nuclear regions after 30 min of
exposure to Epo or removal of T3 (Fig.
9, A and B).
Altering the compartmental balance of Trip-1, therefore, coincided with
enhanced differentiation and reduced replication. Trip-1 also relocated
to the nucleus in JCs cells (data not shown), indicating that
the inhibitory effects of tTrip-1 were not due to impaired nuclear
translocation.

View larger version (88K):
[in this window]
[in a new window]
|
Fig. 9.
Trip-1 subcellular localization changes with
differentiation. A, J2E cells were incubated with or
without T3 (1 µM) before analysis of Trip-1
localization by confocal microscopy. B, J2E cells were
incubated with Epo (5 units) for the indicated times before analysis of
Trip-1 subcellular localization.
|
|
 |
DISCUSSION |
In this article we have demonstrated that Trip-1, a
transcriptional regulator of TR (34, 36), associates with the
tyrosine kinase Lyn in erythroid cells. The interaction between Lyn and Trip-1 was initially identified by a yeast two-hybrid screen and was
confirmed by in vitro binding, co-immunoprecipitations, and intracellular co-localization (Figs. 1 and 2). Because Lyn is involved
in the Epo signaling cascade (27, 29, 32), Trip-1 provides a link
between pathways mediated by cytokine receptors and nuclear hormone receptors.
The parallels between the Trip-1 association with Lyn and TR and the
interaction of p62ORCA with Lck and COUP-TFII are striking.
Like Trip-1 and Lyn, p62ORCA associates with Lck (the
closest Src kinase family member to Lyn) through
phosphotyrosine-independent binding of p62ORCA to the SH2
domain of Lck (49). Furthermore, the Trip-1/TR association (34, 36)
is similar to p62ORCA interacting with the nuclear hormone
receptor COUP-TFII (50), which has been implicated in the regulation of
globin genes (51). Marcus et al. (50) proposed "a role for
ORCA and related factors in mediating cross-talk among distinct signal
transduction pathways important for cellular growth and
differentiation." Here we have provided the biological and
biochemical evidence to support this proposition and have shown that
Trip-1 can modulate pathways activated by Epo and T3.
The dominant negative effects of the truncated Trip-1 were quite
profound, as it simultaneously inhibited Epo-induced differentiation in
immortalized and normal erythroid cells and suppressed
T3-mediated proliferation. The introduction of tTrip-1
resulted in a complete loss of endogenous Lyn, increased
p27Kip1, and an inability to activate T3
response elements. As Trip-1 is also a component of the 26-S proteasome
(45), perhaps the truncated Trip-1 fosters proteasomal degradation of
Lyn. The importance of Trip-1 to the T3 pathway was
illustrated by the suppression of T3 response elements with
the truncated Trip-1.
It is noteworthy that Trip-1 localized with Lyn and TR in the
cytoplasm/plasma membrane of uninduced erythroid cells and then
translocated to discrete nuclear foci within 30 min of Epo stimulation
or after withdrawal of T3. To our knowledge this is the
first description of Trip-1 relocation between subcellular compartments
correlating with enhanced differentiation. Studies are currently under
way to determine the nature of these nuclear structures and their
function during erythroid maturation.
Epo and T3 had major effects on erythroid maturation in
both cell lines and normal progenitors. Whereas Epo promoted
differentiation (manifest by hemoglobin synthesis and morphological
maturation), T3 stimulated proliferation at the expense of
terminal differentiation. Similarly, it has been shown that
T3 prevents hemoglobin production by NFS-60 cells and
increases the erythrocyte yield from erythroblasts (18, 20). Our data
with normal erythroid progenitors confirm that T3 inhibits
colony formation (18). However, we also demonstrated that
T3 is able to expand the erythroid progenitor compartment prior to Epo stimulation, which supports the notion that the effects of
T3 may be stage-specific (18, 19, 24).
Withdrawal of T3 from erythroid cells produced large
increases in erythroid-restricted transcription factors GATA-1, EKLF, and NF-E2, which have been strongly implicated in the control of red
cell maturation, especially in hemoglobin production (52-56). Increasing the concentration of these transcription factors, therefore, promotes differentiation. Cross-regulation of these nuclear proteins may also be important because TR and COUP-TFII together suppress GATA-1 transcription (57), whereas TR is able to associate directly
with NF-E2 (58). Altering the concentration, activity, or combinations
of these DNA proteins can have a major impact upon expression of genes
required for red cell maturation. Removal of T3 also caused
a marked elevation in p27Kip1, which is significant because
entry of erythroid cells into the noncycling, terminally differentiated
state involves increasing p27Kip1 levels (48). Thus,
terminal differentiation was enhanced by the combination of cell cycle
exit and elevated transcription factor levels.
It is conceivable that the Epo/T3 axis provides a
complementary mechanism for expanding erythroid progenitors and
increasing cell numbers before terminal differentiation to generate the
correct number of functionally mature red blood cells. As TR has
been proposed to act as a switch between proliferation and
differentiation (24), Trip-1 may be a vehicle for coordinating the
biological responses initiated by T3 and Epo.
 |
ACKNOWLEDGEMENTS |
Assistance with confocal microscopy was
kindly provided by Dr. P. Rigby (University of Western Australia), and
recombinant human Epo (Eprex) was donated by Drs. J. Adams and J. Patava (Jansen-Cilag). We are indebted to Drs. J. Adams and T. Metz
(Walter and Eliza Hall Institute, Melbourne, Australia) for
providing the cell lines and to Drs. J. Bieker, N. Andrews, S. Watowich, and P. Chambon for generous gifts of antibodies. The plasmids
pDR4-Luc and pF2-Luc were kind gifts from Dr. P. M. Yen (Brigham
and Women's Hospital, Boston, MA).
 |
FOOTNOTES |
*
This work was supported by Grants 980610, 990596, and 139008 from the National Health and Medical Research Council, Australia and by grants from the Medical Research Foundation of Royal Perth Hospital.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Dept. of Biochemistry and Molecular Biology,
College of Medicine, University of South Florida, FL 33612-4799.
¶
Present address: Molecular Genetics of Cancer Division, Walter
and Eliza Hall Institute of Medical Research, Post Office, Royal
Melbourne Hospital, Melbourne, Victoria 3050, Australia.
**
To whom correspondence should be addressed: Laboratory for Cancer
Medicine, University of Western Australia, Level 6, Medical Research
Foundation Bldg., Rear 50 Murray St., Perth WA6000, Australia. Tel.: 61-8-92240334; Fax: 61-8-92240322; E-mail:
pklinken@cyllene.uwa.edu.au.
Published, JBC Papers in Press, September 5, 2001, DOI 10.1074/jbc.M106645200
2
M. Hibbs, personal communication.
 |
ABBREVIATIONS |
The abbreviations used are:
Epo, erythropoietin;
T3, thyroid hormone;
TR, thyroid hormone receptor;
Trip-1, thyroid hormone receptor-interacting protein 1;
tTrip-1, truncated
Trip-1;
SH2 and -3, Src homology 2 and 3;
CFU-E, erythroid
colony-forming units;
BFU-E, erythroid burst-forming units;
GST, glutathione S-transferase;
JAK, Janus kinase;
STAT, signal
transducers and activators of transcription;
MAP, mitogen-activated
protein;
NF-E2, nuclear factor E2;
COUP-TFII, chicken ovalbumin
upstream promoter transcription factor-II;
EKLF, erythroid Kruppel-like
factor;
ORCA, orphan receptor coactivator.
 |
REFERENCES |
| 1.
|
Krantz, S. B.
(1991)
Blood
77,
419-434[Free Full Text]
|
| 2.
|
Dainiak, N.,
Sutter, D.,
and Kreczko, S.
(1978)
Nature
272,
260-262[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
D'Andrea, A. D.,
Lodish, H. F.,
and Wong, G. G.
(1989)
Cell
57,
277-285[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Youssoufian, H.,
Longemore, G.,
Neumann, D.,
Yoshimura, A.,
and Lodish, H. F.
(1993)
Blood
81,
2223-2236[Free Full Text]
|
| 5.
|
Ihle, J. N.,
Quelle, F. W.,
and Miura, O.
(1993)
Semin. Immunol.
5,
375-389[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Wojchowski, D. M.,
Gregory, R. C.,
Miller, C. P.,
Pandit, A. K.,
and Pircher, T. J.
(1999)
Exp. Cell Res.
253,
143-156[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Constantinescu, S. N.,
Ghaffari, S.,
and Lodish, H. F.
(1999)
Trends Endocrinol. Metab.
10,
18-23[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Klingmuller, U.,
Lorenz, U.,
Cantley, L. C.,
Neel, B. G.,
and Lodish, H. F.
(1995)
Cell
80,
729-738[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Starr, R.,
Willson, T. A.,
Viney, E. M.,
Murray, L. J.,
Rayner, J. R.,
Jenkins, B. J.,
Gonda, T. J.,
Alexander, W. S.,
Metcalf, D.,
Nicola, N. A.,
and Hilton, D. J.
(1997)
Nature
387,
917-921[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Yoshimura, A.,
Ohkubo, T.,
Kiguchi, T.,
Jenkins, N. A.,
Gilbert, D. J.,
Copeland, N. G.,
Hara, T.,
and Miyajima, A.
(1995)
EMBO J.
14,
2816-2826[Medline]
[Order article via Infotrieve]
|
| 11.
|
Glass, C. K.
(1994)
Endocr. Rev.
15,
391-407[Abstract/Free Full Text]
|
| 12.
|
Fein, H. G.,
and Rivlin, R. S.
(1975)
Med. Clin. N. Am.
59,
1133-1145[Medline]
[Order article via Infotrieve]
|
| 13.
|
Singh, V.,
and Catlett, J. P.
(1998)
Endocrinologist
8,
87-91
|
| 14.
|
Hentzen, D.,
Renucci, A.,
le Guellec, D.,
Benchaibi, M.,
Jurdic, P.,
Gandrillon, O.,
and Samarut, J.
(1987)
Mol. Cell. Biol.
7,
2416-2424[Abstract/Free Full Text]
|
| 15.
|
Sap, J.,
Munoz, A.,
Damm, K.,
Goldberg, Y.,
Ghysdael, J.,
Leutz, A.,
Beug, H.,
and Vennstrom, B.
(1986)
Nature
324,
635-640[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Weinberger, C.,
Thompson, C. C.,
Ong, E. S.,
Lebo, R.,
Gruol, D. J.,
and Evans, R. M.
(1986)
Nature
324,
641-646[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Malgor, L. A.,
Blanc, C. C.,
Klainer, E.,
Irizar, S. E.,
Torales, P. R.,
and Barrios, L.
(1975)
Blood
45,
671-679[Abstract/Free Full Text]
|
| 18.
|
Perrin, M. C.,
Blanchet, J. P.,
and Mouchiroud, G.
(1997)
Hematol. Cell Ther.
39,
19-26[CrossRef][Medline]
[Order article via Infotrieve]
|
| 19.
|
Schroeder, C.,
Gibson, L.,
Zenke, M.,
and Beug, H.
(1992)
Oncogene
7,
217-227[Medline]
[Order article via Infotrieve]
|
| 20.
|
Zenke, M.,
Munoz, A.,
Sap, J.,
Vennstrom, B.,
and Beug, H.
(1990)
Cell
61,
1035-1049[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Disela, C.,
Glineur, C.,
Bugge, T.,
Sap, J.,
Stengl, G.,
Dodgson, J.,
Stunnenberg, H.,
Beug, H.,
and Zenke, M.
(1991)
Genes Dev.
5,
2033-2047[Abstract/Free Full Text]
|
| 22.
|
Bartunek, P.,
and Zenke, M.
(1998)
Mol. Endocrinol.
12,
1269-1279[Abstract/Free Full Text]
|
| 23.
|
Bauer, A.,
Ulrich, E.,
Andersson, M.,
Beug, H.,
and von Lindern, M.
(1997)
Oncogene
15,
701-715[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Bauer, A.,
Mikulits, W.,
Lagger, G.,
Stengl, G.,
Brosch, G.,
and Beug, H.
(1998)
EMBO J.
17,
4291-303[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Klinken, S. P.,
Nicola, N. A.,
and Johnson, G. R.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
8506-8510[Abstract/Free Full Text]
|
| 26.
|
Busfield, S. J.,
and Klinken, S. P.
(1992)
Blood
80,
412-419[Abstract/Free Full Text]
|
| 27.
|
Tilbrook, P. A.,
Ingley, E.,
Williams, J. H.,
Hibbs, M. L.,
and Klinken, S. P.
(1997)
EMBO J.
16,
1610-1619[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Tilbrook, P. A.,
Bittorf, T.,
Busfield, S. J.,
Chappell, D.,
and Klinken, S. P.
(1996)
J. Biol. Chem.
271,
3453-3459[Abstract/Free Full Text]
|
| 29.
|
Chin, H.,
Arai, A.,
Wakao, H.,
Kamiyama, R.,
Miyasaka, N.,
and Miura, O.
(1998)
Blood
91,
3734-3745[Abstract/Free Full Text]
|
| 30.
|
de Franceschi, L.,
Fumagalli, L.,
Olivieri, O.,
Corrocher, R.,
Lowell, C.,
and Berton, G.
(1997)
J. Clin. Invest.
99,
220-227[Medline]
[Order article via Infotrieve]
|
| 31.
|
Brunati, A. M.,
Bordin, L.,
Clari, G.,
James, P.,
Quadroni, M.,
Baritono, E.,
Pinna, L. A.,
and Donella-Deana, A.
(2000)
Blood
96,
1550-1557[Abstract/Free Full Text]
|
| 32.
|
Tilbrook, P. A.,
Palmer, G. A.,
Bittorf, T.,
Wright, M. J.,
Sarna, M. K.,
Linnekin, D., V., C.,
Williams, J. H.,
Ingley, E.,
Schneider-Mergener, J.,
Krystal, G.,
and Klinken, S. P.
(2001)
Cancer Res.
61,
2453-2458[Abstract/Free Full Text]
|
| 33.
|
Ingley, E.,
Sarna, M. K.,
Beaumont, J. G.,
Tilbrook, P. A.,
Tsai, S.,
Takemoto, Y.,
Williams, J. H.,
and Klinken, S. P.
(2000)
J. Biol. Chem.
275,
7887-7893[Abstract/Free Full Text]
|
| 34.
|
Swaffield, J. C.,
Melcher, K.,
and Johnston, S. A.
(1995)
Nature
374,
88-91[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Lee, J. W., F., R.,
Swaffield, J. C.,
Johnston, S. A.,
and Moore, D. D.
(1995)
Nature
374,
91-94[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
vom Baur, E.,
Zechel, C.,
Herry, D.,
Heine, M. J. S.,
Garnier, J. M.,
Vivat, V.,
Le Douarin, B.,
Gronemeyer, H.,
Chambon, P.,
and Losson, R.
(1996)
EMBO J.
15,
110-124[Medline]
[Order article via Infotrieve]
|
| 37.
|
Metz, T.,
Harris, A. W.,
and Adams, J. M.
(1995)
Cell
82,
29-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Klinken, S. P.,
Rapp, U. R.,
and Morse, H. C., III
(1989)
J. Virol.
63,
1489-1492[Abstract/Free Full Text]
|
| 39.
|
Vojtek, A. B.,
Hollenberg, S. M.,
and Cooper, J. A.
(1993)
Cell
74,
205-214[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Tsai, S.,
Bartelmez, S.,
Sitnicka, E.,
and Collins, S.
(1994)
Genes Dev.
8,
2831-2841[Abstract/Free Full Text]
|
| 41.
|
Fraser, R. A.,
Rossignol, M.,
Heard, D. J.,
Egly, J. M.,
and Chambon, P.
(1997)
J. Biol. Chem.
272,
7122-7126[Abstract/Free Full Text]
|
| 42.
|
Hawley, R. G.,
Lieu, F. H. L.,
Fong, A. Z. C.,
and Hawley, T. S.
(1994)
Gene Ther.
1,
136-138[Medline]
[Order article via Infotrieve]
|
| 43.
|
Williams, J. H.,
Daly, L. N.,
Ingley, E.,
Beaumont, J. G.,
Tilbrook, P. A.,
Lalonde, J. P.,
Stillitano, J. P.,
and Klinken, S. P.
(1999)
EMBO J.
18,
5559-5566[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Yen, P. M.,
Liu, Y.,
Sugawara, A.,
and Chin, W. W.
(1996)
J. Biol. Chem.
271,
10910-10916[Abstract/Free Full Text]
|
| 45.
|
Rubin, D. M.,
Coux, O.,
Wefes, I.,
Hengartner, C.,
Young, R. A.,
Goldberg, A. L.,
and Finley, D.
(1996)
Nature
379,
655-657[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Zhu, X. G.,
Hanover, J. A.,
Hager, G. L.,
and Cheng, S. Y.
(1998)
J. Biol. Chem.
273,
27058-27063[Abstract/Free Full Text]
|
| 47.
|
Fero, M. L.,
Rivkin, M.,
Tasch, M.,
Porter, P.,
Carow, C. E.,
Firpo, E.,
Polyak, K.,
Tsai, L. H.,
Broudy, V.,
Perlmutter, R. M.,
Kaushansky, K.,
and Roberts, J. M.
(1996)
Cell
85,
733-744[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Hsieh, F. F.,
Barnett, L.,
Green, W. F.,
Freedman, K.,
Matushansky, I.,
Skoultchi, A. I.,
and Kelley, L. L.
(2000)
Blood
96,
2746-2754[Abstract/Free Full Text]
|
| 49.
|
Park, I.,
Chung, J.,
Walsh, C. T.,
Yun, Y.,
Strominger, J. L.,
and Shin, J.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
12338-12342[Abstract/Free Full Text]
|
| 50.
|
Marcus, S. L.,
Winrow, C. J.,
Capone, J. P.,
and Rachubinski, R. A.
(1996)
J. Biol. Chem.
271,
27197-27200[Abstract/Free Full Text]
|
| 51.
|
Filipe, A.,
Li, Q. L.,
Deveaux, S.,
Godin, I.,
Romeo, P. H.,
Stamatoyannopoulos, G.,
and Mignotte, V.
(1999)
EMBO J.
18,
687-697[CrossRef][Medline]
[Order article via Infotrieve]
|
| 52.
|
Miller, I. J.,
and Bieker, J. J.
(1993)
Mol. Cell. Biol.
13,
2776-2786[Abstract/Free Full Text]
|
| 53.
|
Tsai, S.,
Martin, D. I. K.,
Zon, L. I.,
D'Andrea, A. D.,
Wong, G. G.,
and Orkin, S. H.
(1989)
Nature
339,
446-451[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Perkins, A. C.,
Sharpe, A. H.,
and Orkin, S. H.
(1995)
Nature
375,
318-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Nuez, B.,
Michalovich, D.,
Bygrave, A.,
Ploemacher, R.,
and Grosveld, F.
(1995)
Nature
375,
316-318[CrossRef][Medline]
[Order article via Infotrieve]
|
| 56.
|
Andrews, N. C.,
Erdjument-Bromage, H.,
Davidson, M. B.,
Tempst, P.,
and Orkin, S. H.
(1993)
Nature
362,
722-728[CrossRef][Medline]
[Order article via Infotrieve]
|
| 57.
|
Trainor, C. D.,
Evans, T.,
and Felsenfeld, G.
(1995)
Mol. Endocrinol.
9,
1135-1146[Abstract/Free Full Text]
|
| 58.
|
Cheng, X.,
Reginato, M. J.,
Andrews, N. C.,
and Lazar, M. A.
(1997)
Mol. Cell. Biol.
17,
1407-1416[Abstract]
|
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. L. Samuels, S. P. Klinken, and E. Ingley
Liar, a novel Lyn-binding nuclear/cytoplasmic shuttling protein that influences erythropoietin-induced differentiation
Blood,
April 16, 2009;
113(16):
3845 - 3856.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. K. Williams, I. S. Lucet, S. P. Klinken, E. Ingley, and J. Rossjohn
Crystal Structures of the Lyn Protein Tyrosine Kinase Domain in Its Apo- and Inhibitor-bound State
J. Biol. Chem.,
January 2, 2009;
284(1):
284 - 291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Kendrick, C. J. Payne, M. R. Epis, J. R. Schneider, P. J. Leedman, S. P. Klinken, and E. Ingley
Erythroid defects in TR{alpha}-/- mice
Blood,
March 15, 2008;
111(6):
3245 - 3248.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Endersby, I. J. Majewski, L. Winteringham, J. G. Beaumont, A. Samuels, R. Scaife, E. Lim, M. Crossley, S. P. Klinken, and J.-P. Lalonde
Hls5 regulated erythroid differentiation by modulating GATA-1 activity
Blood,
February 15, 2008;
111(4):
1946 - 1950.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ingley, J. R. Schneider, C. J. Payne, D. J. McCarthy, K. W. Harder, M. L. Hibbs, and S. P. Klinken
Csk-binding Protein Mediates Sequential Enzymatic Down-regulation and Degradation of Lyn in Erythropoietin-stimulated Cells
J. Biol. Chem.,
October 20, 2006;
281(42):
31920 - 31929.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2001 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|